Literature DB >> 15041077

Acceptance of flexible sigmoidoscopy screening for colorectal cancer.

Daniel E Montaño1, Joseph V Selby, Carol P Somkin, Aradhana Bhat, Marion Nadel.   

Abstract

This study was conducted in the Kaiser Permanente Medical Care Program of Northern California to identify patient characteristics that explain interest in flexible sigmoidoscopy (FS) screening. A mailed screening invitation to 6837 age-eligible patients elicited responses from 49%. Efforts to reach and interview both eligible respondents and non-respondents resulted in 2728 computer-assisted telephone interviews (CATI), with 60% indicating interest in FS screening. Five components of the Integrated Behavioral Model were measured with respect to FS screening: attitude, affect, social influence, facilitators/barriers, and perceived risk of colorectal cancer. All five model components were significantly and independently associated with interest in FS, with patient attitude being the strongest predictor. Of the 32 items comprising the model components, nine items having the highest correlations with FS interest were identified as potentially important issues to address by efforts to increase interest in screening. Six of these were attitudinal beliefs. The findings from this theory-driven study provide specific targets for the design of interventions to increase FS interest and screening rates.

Entities:  

Mesh:

Year:  2004        PMID: 15041077     DOI: 10.1016/j.cdp.2003.11.005

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  8 in total

Review 1.  Individual-level factors in colorectal cancer screening: a review of the literature on the relation of individual-level health behavior constructs and screening behavior.

Authors:  Marc T Kiviniemi; Alyssa Bennett; Marie Zaiter; James R Marshall
Journal:  Psychooncology       Date:  2010-10-27       Impact factor: 3.894

2.  An evaluation of colonoscopy use: implications for health education.

Authors:  Chia-Ching Chen; Charles E Basch; Tetsuji Yamada
Journal:  J Cancer Educ       Date:  2010-06       Impact factor: 2.037

3.  Study protocol: the Adherence and Intensification of Medications (AIM) study--a cluster randomized controlled effectiveness study.

Authors:  Michele Heisler; Timothy P Hofer; Mandi L Klamerus; Julie Schmittdiel; Joe Selby; Mary M Hogan; Hayden B Bosworth; Adam Tremblay; Eve A Kerr
Journal:  Trials       Date:  2010-10-12       Impact factor: 2.279

4.  Primary care practice organization influences colorectal cancer screening performance.

Authors:  Elizabeth M Yano; Lynn M Soban; Patricia H Parkerton; David A Etzioni
Journal:  Health Serv Res       Date:  2007-06       Impact factor: 3.402

5.  Adult daughters' reports of breast cancer risk reduction and early detection advice received from their mothers: an exploratory study.

Authors:  Pamela S Sinicrope; Christi A Patten; Lara P Clark; Tabetha A Brockman; Emily E Rock; Marlene H Frost; Larra R Petersen; Robert A Vierkant; Celine M Vachon; Zachary S Fredericksen; Carol A Janney; Thomas A Sellers; James R Cerhan
Journal:  Psychooncology       Date:  2009-02       Impact factor: 3.894

6.  Are gender-associated differences in quality of life in colorectal cancer patients disease-specific?

Authors:  Johannes Giesinger; Georg Kemmler; Verena Mueller; August Zabernigg; Beate Mayrbaeurl; Josef Thaler; Dietmar Ofner; Christian Pegger; Gerhard Rumpold; Barbara Weber; Barbara Sperner-Unterweger; Bernhard Holzner
Journal:  Qual Life Res       Date:  2009-04-01       Impact factor: 4.147

7.  Factors associated with intentions to adhere to colorectal cancer screening follow-up exams.

Authors:  Ying-Fang Zheng; Tami Saito; Miyako Takahashi; Teruo Ishibashi; Ichiro Kai
Journal:  BMC Public Health       Date:  2006-11-06       Impact factor: 3.295

8.  Acceptability of cancer chemoprevention trials: impact of the design.

Authors:  Anne-Sophie Maisonneuve; Laetitia Huiart; Laetitia Rabayrol; Doug Horsman; Remi Didelot; Hagay Sobol; Francois Eisinger
Journal:  Int J Med Sci       Date:  2008-08-22       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.